Day: January 13, 2022

BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China. “We are excited that Angel has begun to enroll patients in its Phase 1/1b clinical trial of CPI-818, which marks the first clinical use of one of our drug candidates in China,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “There is a significant opportunity to address unmet clinical need in China, where TCL are more common than in North America. In addition,...

New Syndicated CHR Evening Show Debuts January 17 NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) — CUMULUS MEDIA’s (NASDAQ: CMLS) Westwood One will introduce “Eliott & Nina” a new Contemporary Hit Radio show to broadcast live from Westwood One’s Atlanta studios beginning Monday, January 17. Each weeknight from 7 p.m. to 12 midnight, Eliott and Nina will engage listeners with content targeting young adults including today’s hottest hits, celebrity and artist updates, pop culture news, listener calls, and extensive social media integrations. “Eliott and Nina are poised to reimagine and recharge nighttime CHR,” said Brian Philips, Executive Vice President of Content and Audience. “Bringing chemistry, comedy and cultural relevance, they will light up every platform with this fast-paced new entry.” “Eliott and Nina are the perfect duo...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Reference is made to the stock exchange notice from Green Energy Group (SeaBird Exploration PLC ) (the “Company”) on 13 January 2021 regarding a private placement of new shares in the Company (the “Private Placement”) and a possible subsequent offering at the same subscription price as in the Private Placement (the “Subsequent Offering”).Date on which the terms and conditions of the potential Subsequent Offering were announced: 14 January 2022Last day including right:         13 January 2022Ex-date: 14 January 2022Record Date:         17 January 2022Maximum...

SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, capped off the last day of 2022 Symposium, the Company’s premiere event showcasing OGM research applications across key clinical areas of constitutional genetic disease, hematologic malignancies, solid tumors and OGM combined with next-generation sequencing (NGS). Today’s presentations demonstrated that the combination of OGM and NGS can reveal more answers than NGS alone, with cost-effective, scalable, sensitive, accurate and comprehensive genome analysis for genetic disease and cancer research. NGS is unable to accurately measure structural variants (SVs), which...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange release by SeaBird Exploration PLC (“SeaBird” or the “Company”) on 13 January 2022 regarding the intention to carry out a private placement (the “Private Placement”) of new shares in the Company. The Company is pleased to announce that the Private Placement has been successfully placed, and that it has allocated subscriptions for 14,000,000 offer shares (the “Offer Shares”) at a subscription price per share of NOK 2.25 (the...

New York, NY, Jan. 13, 2022 (GLOBE NEWSWIRE) — Papaya Growth Opportunity Corp. I (the “Company”), a newly incorporated blank check company, today announced the pricing of its initial public offering of 25,000,000 units at a price of $10.00 per unit. The units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “PPYAU” beginning January 14, 2022. The Company’s management team is led by Chairperson Patrick Pohlen, Chief Executive Officer Clay Whitehead, President Alexander Spiro, and Chief Financial Officer and Secretary Daniel Rogers. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination...

Highlights:Flowr exported first shipment of premium medical cannabis to Israel for $825,000. The shipment represents the Company’s first export into an international market. Holigen in Portugal expects first harvest of indoor grown cannabis in mid-January 2022 with initial in-process testing at more than 29% THC content.TORONTO, Jan. 13, 2022 (GLOBE NEWSWIRE) — The Flowr Corporation (“Flowr” or the “Company”) (TSXV: FLWR, OTC: FLWPF) is pleased to announce that it has completed its first shipment from Canada to Israel, as part of the previously announced international supply agreement (the “Supply Agreement”) with Focus Medical Herbs Ltd. (“Focus Medical”), a company which IM Cannabis Corp. (NASDAQ: IMCC) (CSE:IMCC) (“IMC”) has an exclusive commercial agreement with in Israel. The first shipment consisted of premium cannabis...

CALGARY, Alberta, Jan. 13, 2022 (GLOBE NEWSWIRE) — EarthRenew Inc. (CSE: ERTH; OTCQB: VVIVF; Frankfurt: WIMN) (“EarthRenew ” or the “ Company ”), a Canadian fertilizer company supporting regenerative agriculture practices, today published positive results from its previously announced field trial collaboration between the Company’s subsidiary, Replenish Nutrients, Lethbridge College, and Biome Makers. Data highlights:Production of healthier potatoes with Rebuilder – free from common defects Rebuilder achieved equivalent marketable yield compared to a standard synthetic fertilizer program at a lower nutrient cost while rebuilding soil health Improved microbial diversity and variety in the soil over standard synthetic fertilizer Increasing trend in phytohormone production (in particular gibberellin, auxin and cytokinin)Conducted...

DEERFIELD, Ill., Jan. 13, 2022 (GLOBE NEWSWIRE) — Surgalign Holdings, Inc. (NASDAQ: SRGA), a global medical technology company focused on elevating the standard of care through the evolution of digital health, today announced that the management team will participate in a fireside chat at the Sidoti Virtual Small Cap Conference on Thursday, January 20, 2022. The Company is scheduled to present at 11:30 a.m. Eastern Time the same day via webcast. A live audio webcast of the conference fireside chat will be available online through the investor relations page of the Company’s website at surgalign.com/investors/. A replay of the webcast will be archived on the website. About Surgalign Holdings, Inc. Surgalign Holdings, Inc. is a global medical technology company committed to the promise of digital health to drive transformation across...

CONWAY, Ark., Jan. 13, 2022 (GLOBE NEWSWIRE) — Home BancShares, Inc. (NYSE: HOMB) (“Home” or the “Company”), parent company of Centennial Bank, (“Centennial”), announced today the pricing of $300 million of its 3.125% fixed-to-floating rate subordinated notes due 2032 (the “Notes”). The Notes will initially bear interest at 3.125% per annum, payable semiannually in arrears, commencing on the issue date, to, but excluding, January 30, 2027. Commencing January 30, 2027, the interest rate on the Notes will reset quarterly to a floating rate per annum equal to a benchmark rate that is expected to be Three-Month Term SOFR (which is defined in the Notes) plus 182 basis points, payable quarterly in arrears. The Company may redeem the Notes, in whole or in part, after January 30, 2027, at a price equal to 100% of the principal amount of...